(S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma
US-9993449-B2 · Jun 12, 2018 · US
US10836708B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10836708-B2 |
| Application number | US-201916423761-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 28, 2019 |
| Priority date | May 25, 2018 |
| Publication date | Nov 17, 2020 |
| Grant date | Nov 17, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are processes, compounds and compositions for making (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid. Also provided herein a pharmaceutical compositions containing (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid.
Opening claim text (preview).
What is claimed is: 1. A process for preparing (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (1) or salt thereof comprising: converting (1R,4S)-(−)-2-azabicyclo[2.2.1]hept-5-en-3-one (2) to (1R,4S)-(−)-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]hept-5-en-3-one (3); converting (1R,4S)-(−)-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]hept-5-en-3-one (3) to (1R,4R,6S,7R)-(+)-7-bromo-2-(4-methoxybenzyl)-3-oxo-2-azabicyclo[2.2.1]heptan-6-yl acetate (4); converting (1R,4R,6S,7R)-(+)-7-bromo-2-(4-methoxybenzyl)-3-oxo-2-azabicyclo[2.2.1]heptan-6-yl acetate (4) to (1R,4R,6S,7R)-(+)-7-Bromo-6-hydroxy-2-(4-methoxybenzyl)-2-aza-bicyclo[2.2.1]heptan-3-one (25); converting (1R,4R,6S,7R)-(+)-7-Bromo-6-hydroxy-2-(4-methoxybenzyl)-2-aza-bicyclo[2.2.1]heptan-3-one (25) to (1R,4R,7R)-(+)-7-bromo-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]heptane-3,6-dione (5); converting (1R,4R,7R)-(+)-7-bromo-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]heptane-3,6-dione (5) to (1R,4R,7R)-(+)-7-bromo-6-(difluoromethylene)-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]heptan-3-one (6); converting (1R,4R,7R)-(+)-7-brom o-6-(difluoromethylene)-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]heptan-3-one (6) to (1R,4R,7R)-(+)-7-bromo-6-(difluoromethylene)-2-azabicyclo[2.2.1]heptan-3-one (7); converting (1R,4R,7R)-(+)-7-bromo-6-(difluoromethylene)-2-azabicyclo[2.2.1]heptan-3-one (7) to (1R,4R,7R)-(+)-7-bromo-6-(difluoromethylene)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]heptan-3-one (8); converting (1R,4R,7R)-7-bromo-6-(difluoromethylene)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]heptan-3-one (8) to (S)-3-((tent-butoxycarbonyl)amino)-4-(difluoromethylene)cyclopent-1-ene-1-carboxylic acid (19); and converting (S)-3-((tent-butoxycarbonyl)amino)-4-(difluoromethylene)cyclopent-1-ene-1-carboxylic acid (19) to (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (1), optionally followed by acidification to provide the hydrochloride salt thereof. 2. A process for preparing (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (1) or salt thereof comprising: converting (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one (2) to (1R,4R,6S,7R)-7-bromo-2-(4-methoxybenzyl)-3-oxo-2-azabicyclo[2.2.1]heptan-6-yl acetate (4); converting (1R,4R,6S,7R)-7-bromo-2-(4-methoxybenzyl)-3-oxo-2-azabicyclo[2.2.1]heptan-6-yl acetate (4) to (1R,4R,7R)-7-bromo-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]heptane-3,6-dione (5); converting (1R,4R,7R)-7-bromo-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]heptane-3,6-dione (5) to (1R,4R,7R)-7-bromo-6-(difluoromethylene)-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]heptan-3-one (6); converting (1R,4R,7R)-7-bromo-6-(difluoromethylene)-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]heptan-3-one (6) to (1R,4R,7R)-7-bromo-6-(difluoromethylene)-2-azabicyclo[2.2.1]heptan-3-one (7); converting (1R,4R,7R)-7-bromo-6-(difluoromethylene)-2-azabicyclo[2.2.1]heptan-3-one (7) to (1R,4R,7R)-7-bromo-6-(difluoromethylene)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]heptan-3-one (8); converting (1R,4R,7R)-7-bromo-6-(difluoromethylene)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]heptan-3-one (8) to methyl (S)-3-((tert-butoxycarbonyl)amino)-4-(difluoromethylene)cyclopent-1-ene-1-carboxylate (9); and converting methyl (S)-3-((tert-butoxycarbonyl)amino)-4-(difluoromethylene)cyclopent-1-ene-1-carboxylate (9) to (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (1), optionally followed by acidification to provide the hydrochloride salt thereof. 3. The process according to claim 2 , wherein (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one (2) is converted to (1R,4S)-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]hept-5-en-3-one (3); and (1R,4S)-2-(4-methoxybenzyl)-2-azabicyclo[2.2.1]hept-5-en-3-one (3) is converted to (1R,4R,6S,7R)-7-bromo-2-(4-methoxybenzyl)-3-oxo-2-azabicyclo[2.2.1]heptan-6-yl acetate (4).
Optical isomers · CPC title
Antineoplastic agents · CPC title
for treating abuse or dependence · CPC title
Antiepileptics; Anticonvulsants · CPC title
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.